Rituxan: remission in ANCA-associated vasculitis?
Rituximab holds promise in the treatment of severe antineutrophilic cytoplasmic antibody-associated vasculitis, according to an open-label pilot study.
http://www.medscape.com/viewarticle/537972...
|
Rituximab-induced vasculitis. [Dermatology. 2001] - PubMed Result
PubMed is a service of the US National Library of Medicine that includes over 18 million citations from MEDLINE and other life science journals for ...
http://www.ncbi.nlm.nih.gov/pubmed/11549810...
|
A Review of Rituximab in Cutaneous Medicine
Several reports note that rituximab can cause serum sickness.[86] Rituximab- induced vasculitis has been reported.[87] Lowndes reported a case of ...
http://www.medscape.com/viewarticle/523577_4...
|
RiTUXimab: Drug Information Provided by Lexi-Comp: Merck Manual ...
The rituximab dose for rheumatoid arthritis is a flat dose (1000 mg) and is not .... systemic vasculitis, toxic epidermal necrolysis, tumor lysis syndrome, ...
http://www.merck.com/mmpe/lexicomp/rituximab.html...
|
A Review of Rituximab in Cutaneous Medicine
[34,35,36] In a study of 15 people, Rituximab proved an effective treatment of cryoglobulinemia with skin vasculitis manifestations (ulcers, purpura, ...
http://www.medscape.com/viewarticle/523577_3...
|
Kidney International - Rituximab in the treatment of anti ...
Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future ...
http://www.nature.com/ki/journal/v72/n6/full/5002395a.html...
|
A Review of Rituximab in Cutaneous Medicine
2 Mar 2006 ... Rituximab is a promising treatment for systemic lupus erythematosus, dermatomyositis, pemphigus, vasculitis, and a variety of hematologic ...
http://www.medscape.com/viewarticle/523577...
|
Rituximab induces remission in refractory HCV associated ...
Rituximab offers a new possibility for inducing remission in refractory HCV associated cryoglobulinaemic vasculitis and the lymphoproliferative disorder. ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=17...
|
Rituximab for the Treatment of Hepatitis C Associated ...
Age 18-75 years with documented HCV; Objective evidence of vasculitis ... contraception during study and for 12 months following Rituximab treatment ...
http://www3.niaid.nih.gov/Volunteer/HIVandInfectious/ViralHe...
|
Clinical Study: 02-I-0096, Rituximab (Anti-CD20) for the Treatment ...
Patients whose cryoglobulinemic vasculitis improves and remains inactive for 12 months after completing Rituximab therapy will have completed the study. ...
http://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2002-I-...
|